Pivotal Device Trial Guidance Said to Omit Key Information

Clinical Trials Advisor
Besides lacking key information on confidentiality, a draft guidance seems to imply the FDA prefers randomized studies over other trial designs for pivotal studies of devices pursuing premarket approval and poses impossible barriers for trial manager, according to comments on the document.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00